Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: A 3-year, double-blind, placebo-controlled clinical trial

被引:57
作者
Greenspan, SL
Beck, TJ
Resnick, NM
Bhattacharya, R
Parker, RA
机构
[1] Univ Pittsburgh, Osteoporosis Prevent & Treatment Ctr, Dept Med, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Inst Aging, Pittsburgh, PA 15213 USA
[4] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA
[5] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA
关键词
aging; estrogens; bone densitometry; osteoporosis; bisphosphonates;
D O I
10.1359/JBMR.050508
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Introduction: Fracture reduction is only partially explained by increased BMD. The aim of this study was to examine changes in structural geometry of the hip, derived from DXA in postmenopausal women after treatment with antiresorptive agents. Materials and Methods: This was a double-blind, placebo-controlled, randomized clinical trial of 373 women over the age of 65 years, who were randomized to hormone replacement therapy, alendronate, combination therapy, or placebo for 3 years. The outcomes included the DXA-derived hip structure analysis program by Beck, which is an engineering interpretation of the DXA data. The indices included cross-sectional area, section modulus (a measure of bending strength), outer diameter, cortical thickness, and buckling ratio (an index of cortical bone stability). Properties were measured in cross-sectional regions traversing the femur at the narrowest point on the femoral neck, the intertrochanteric region, and the proximal shaft. Results: In the femoral neck, improvement in the hip structure analysis indices were generally significantly greater with combination therapy than either monotherapy; increases were also greater at the intertrochanter compared with hormone replacement therapy. For example, the section modulus at the intertrochanter and narrow neck increased 10.6% and 10.3%, respectively, with combination therapy, 9.1% and 7.3% with alendronate, 5.8% and 6.9% with hormone replacement therapy, and 3.4% and 3.2% with placebo (p < 0.01 across the four groups). Buckling ratio increased, suggesting decreased stability in the placebo group, whereas there was either no change or significant improvements (p < 0.05) in each active treatment group. Conclusions: We conclude that changes in the distribution of bone mass underlying the improvements in density with antiresorptive agents in combination or alone have positive effects on structural strength and stability at the proximal femur. This study provides additional information on the potential mechanisms for fracture reduction with antiresorptive agents.
引用
收藏
页码:1525 / 1532
页数:8
相关论文
共 31 条
[1]
Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[2]
SEX-DIFFERENCES IN GEOMETRY OF THE FEMORAL-NECK WITH AGING - A STRUCTURAL-ANALYSIS OF BONE-MINERAL DATA [J].
BECK, TJ ;
RUFF, CB ;
SCOTT, WW ;
PLATO, CC ;
TOBIN, JD ;
QUAN, CA .
CALCIFIED TISSUE INTERNATIONAL, 1992, 50 (01) :24-29
[3]
Effects of current and discontinued estrogen replacement therapy on hip structural geometry: The study of osteoporotic fractures [J].
Beck, TJ ;
Stone, KL ;
Oreskovic, TL ;
Hochberg, MC ;
Nevitt, MC ;
Genant, HK ;
Cummings, SR .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (11) :2103-2110
[4]
Structural trends in the aging femoral neck and proximal shaft: Analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data [J].
Beck, TJ ;
Looker, AC ;
Ruff, CB ;
Sievanen, H ;
Wahner, HW .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (12) :2297-2304
[5]
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[6]
Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women [J].
Boivin, G ;
Lips, P ;
Ott, SM ;
Harper, KD ;
Sarkar, S ;
Pinette, KV ;
Meunier, PJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4199-4205
[7]
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women [J].
Boivin, GY ;
Chavassieux, PM ;
Santora, AC ;
Yates, J ;
Meunier, PJ .
BONE, 2000, 27 (05) :687-694
[8]
Meta-analysis of alendronate for the treatment of postmenopausal women [J].
Cranney, A ;
Wells, G ;
Willan, A ;
Griffith, L ;
Zytaruk, N ;
Robinson, V ;
Black, D ;
Adachi, J ;
Shea, B ;
Tugwell, P ;
Guyatt, G .
ENDOCRINE REVIEWS, 2002, 23 (04) :508-516
[9]
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs [J].
Cummings, SR ;
Karpf, DB ;
Harris, F ;
Genant, HK ;
Ensrud, K ;
LaCroix, AZ ;
Black, DM .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04) :281-289
[10]
Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy [J].
Delmas, PD ;
Seeman, E .
BONE, 2004, 34 (04) :599-604